{% extends "clinical-protocol/master-protocol.j2" %}

{% block title %}
INVESTIGATIONAL BIOLOGIC PRODUCT PROTOCOL
{{ study_name | upper }}
IND Number: {{ ind_number | default("PENDING") }}
Protocol Number: {{ protocol_number }}
{% endblock %}

{% block content %}
{{ super() }}

## BIOLOGIC-SPECIFIC SECTIONS

### A. INVESTIGATIONAL BIOLOGIC INFORMATION

#### Biologic Name
{{ biologic_name }} ({{ biologic_type | default("monoclonal antibody, vaccine, gene therapy, etc.") }})

#### Product Classification
{{ biologic_classification | default("Therapeutic biologic product") }}

#### Source and Production
{{ biologic_source | default("Produced in mammalian cell culture") }}

#### Formulation and Presentation
{{ biologic_formulation | default("Sterile solution for injection") }}

#### Route of Administration
{{ route_of_administration | default("Intravenous infusion") }}

#### Dosing Regimen
{{ dosing_regimen | default("Dose calculated based on body weight or surface area") }}

### B. PRODUCT CHARACTERIZATION

#### Molecular Characteristics
{{ molecular_characteristics | default("Molecular weight, structure, and composition...") }}

#### Biological Activity
{{ biological_activity | default("Mechanism of action and target specificity...") }}

#### Immunogenicity
{{ immunogenicity_profile | default("Potential for immune response and antibody formation...") }}

### C. MANUFACTURING AND QUALITY

#### Manufacturing Process
{{ manufacturing_process | default("Produced using recombinant DNA technology in CHO cells") }}

#### Product Specifications
{{ product_specifications | default("Identity, purity, potency, and safety specifications") }}

#### Lot Release Criteria
{{ lot_release_criteria | default("Each lot tested for sterility, endotoxin, and potency") }}

#### Viral Safety
{{ viral_safety | default("Viral clearance validation and testing performed") }}

### D. NONCLINICAL STUDIES

#### Pharmacology Studies
{{ pharmacology_summary | default("Primary and secondary pharmacology in relevant models...") }}

#### Toxicology Program
{{ toxicology_program | default("Single and repeat-dose toxicity studies...") }}

#### Immunotoxicity
{{ immunotoxicity | default("Assessment of immune system effects...") }}

#### Species Selection Rationale
{{ species_rationale | default("Relevant species selected based on target binding...") }}

### E. CLINICAL EXPERIENCE

#### Prior Clinical Studies
{{ prior_clinical_studies | default("Phase 1/2 studies have shown...") }}

#### Dose Selection Rationale
{{ dose_selection | default("Dose selected based on PK/PD modeling and prior studies") }}

#### Immunogenicity Monitoring
{{ immunogenicity_monitoring | default("Anti-drug antibodies will be assessed at specified timepoints") }}

### F. PRODUCT HANDLING AND ADMINISTRATION

#### Storage Requirements
{{ storage_requirements | default("Store at 2-8Â°C, do not freeze, protect from light") }}

#### Preparation Instructions
{{ preparation_instructions | default("Dilute in 0.9% sodium chloride to final concentration...") }}

#### Administration Guidelines
{{ administration_guidelines | default("Infuse over specified time with monitoring...") }}

#### Infusion Reactions Management
{{ infusion_reaction_management | default("Pre-medication and management of infusion reactions...") }}

### G. SPECIAL CONSIDERATIONS

#### Contraception Requirements
{{ contraception_requirements | default("Due to unknown effects on fetus, adequate contraception required") }}

#### Pregnancy and Lactation
{{ pregnancy_lactation | default("Women of childbearing potential must have negative pregnancy test") }}

#### Immunosuppression Considerations
{{ immunosuppression | default("Live vaccines contraindicated during treatment period") }}

#### Long-term Follow-up
{{ longterm_followup | default("Subjects followed for immunogenicity and delayed adverse events") }}

### H. BIOSAFETY

#### Handling Precautions
{{ handling_precautions | default("Universal precautions for handling biological products") }}

#### Waste Disposal
{{ waste_disposal | default("Dispose of product and materials per institutional biosafety guidelines") }}

#### Occupational Exposure
{{ occupational_exposure | default("Report any accidental exposure to study product") }}

### I. REGULATORY CONSIDERATIONS

#### FDA Guidance Compliance
Study conducted in accordance with FDA guidance for biological products

#### International Standards
{{ international_standards | default("Compliant with ICH guidelines for biotechnology products") }}

#### Biosimilar Considerations
{{ biosimilar_info | default("Not applicable" if biologic_type != "biosimilar" else "Biosimilarity assessment per FDA guidance") }}

{% endblock %}